Literature DB >> 1656851

Binding affinities of structurally related human rhinovirus capsid-binding compounds are related to their activities against human rhinovirus type 14.

M P Fox1, M A McKinlay, G D Diana, F J Dutko.   

Abstract

The binding affinities (Kds) and the rates of association and dissociation of members of a chemical class of antiviral compounds at their active sites in human rhinovirus type 14 (HRV-14) were determined. On the basis of analysis by LIGAND, a nonlinear curve-fitting program, of saturation binding experiments with HRV-14, the Kds for Win 52084, Win 56590, disoxaril (Win 51711), and Win 54954 were found to be 0.02, 0.02, 0.08, and 0.22 microM, respectively. The independently determined kinetic rates of association and dissociation resulted in calculated Kd values which were in agreement with the Kd values determined in saturation binding experiments. Scatchard plots of each of four compounds for the binding data indicated that approximately 40 to 60 molecules were bound per HRV-14 virion. Hill plots showed no evidence of cooperativity in binding. Furthermore, the antiviral activities (MICs in plaque reduction assays with HRV-14) for this limited series of compounds (n = 4) correlated well (r = 0.997) with the observed Kds. Likewise, the absence of detectable binding of Win 54954 to the drug-resistant mutant HRV-14 (Leu-1188) corresponded to a lack of antiviral activity. The positive relationship between the antiviral activities and the Kds that were determined may have implications for the molecular design of capsid-binding antirhinovirus drugs.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1656851      PMCID: PMC284283          DOI: 10.1128/AAC.35.6.1040

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  24 in total

1.  Inhibition of poliovirus uncoating by disoxaril (WIN 51711).

Authors:  H Zeichhardt; M J Otto; M A McKinlay; P Willingmann; K O Habermehl
Journal:  Virology       Date:  1987-09       Impact factor: 3.616

2.  Lack of quantitative correlation between inhibition of replication of rhinoviruses by an antiviral drug and their stabilization.

Authors:  K Andries; B Dewindt; J Snoeks; R Willebrords
Journal:  Arch Virol       Date:  1989       Impact factor: 2.574

3.  Genetic and molecular analyses of spontaneous mutants of human rhinovirus 14 that are resistant to an antiviral compound.

Authors:  B A Heinz; R R Rueckert; D A Shepard; F J Dutko; M A McKinlay; M Fancher; M G Rossmann; J Badger; T J Smith
Journal:  J Virol       Date:  1989-06       Impact factor: 5.103

4.  Crystal structure of human rhinovirus serotype 1A (HRV1A).

Authors:  S S Kim; T J Smith; M S Chapman; M C Rossmann; D C Pevear; F J Dutko; P J Felock; G D Diana; M A McKinlay
Journal:  J Mol Biol       Date:  1989-11-05       Impact factor: 5.469

5.  Synthesis and structure-activity studies of some disubstituted phenylisoxazoles against human picornavirus.

Authors:  G D Diana; D Cutcliffe; R C Oglesby; M J Otto; J P Mallamo; V Akullian; M A McKinlay
Journal:  J Med Chem       Date:  1989-02       Impact factor: 7.446

Review 6.  The canyon hypothesis. Hiding the host cell receptor attachment site on a viral surface from immune surveillance.

Authors:  M G Rossmann
Journal:  J Biol Chem       Date:  1989-09-05       Impact factor: 5.157

7.  Conformational change in the floor of the human rhinovirus canyon blocks adsorption to HeLa cell receptors.

Authors:  D C Pevear; M J Fancher; P J Felock; M G Rossmann; M S Miller; G Diana; A M Treasurywala; M A McKinlay; F J Dutko
Journal:  J Virol       Date:  1989-05       Impact factor: 5.103

8.  In vitro and in vivo activities of WIN 54954, a new broad-spectrum antipicornavirus drug.

Authors:  M G Woods; G D Diana; M C Rogge; M J Otto; F J Dutko; M A McKinlay
Journal:  Antimicrob Agents Chemother       Date:  1989-12       Impact factor: 5.191

9.  Human rhinovirus 14 complexed with antiviral compound R 61837.

Authors:  M S Chapman; I Minor; M G Rossmann; G D Diana; K Andries
Journal:  J Mol Biol       Date:  1991-02-05       Impact factor: 5.469

10.  Enantiomeric effects of homologues of disoxaril on the inhibitory activity against human rhinovirus-14.

Authors:  G D Diana; M J Otto; A M Treasurywala; M A McKinlay; R C Oglesby; E G Maliski; M G Rossmann; T J Smith
Journal:  J Med Chem       Date:  1988-03       Impact factor: 7.446

View more
  7 in total

1.  Analysis of three structurally related antiviral compounds in complex with human rhinovirus 16.

Authors:  A T Hadfield; G D Diana; M G Rossmann
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-21       Impact factor: 11.205

2.  SCH 48973: a potent, broad-spectrum, antienterovirus compound.

Authors:  P J Buontempo; S Cox; J Wright-Minogue; J L DeMartino; A M Skelton; E Ferrari; R Albin; E J Rozhon; V Girijavallabhan; J F Modlin; J F O'Connell
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

3.  Method for detection of picornavirus capsid binders with soluble intercellular adhesion molecule 1.

Authors:  K Last-Barney; S D Marlin; K Pal; C Cahill-Feehan; E J McNally; D D Jeanfavre; V J Merluzzi
Journal:  Antimicrob Agents Chemother       Date:  1993-08       Impact factor: 5.191

4.  Structural and virological studies of the stages of virus replication that are affected by antirhinovirus compounds.

Authors:  Ying Zhang; Alan A Simpson; Rebecca M Ledford; Carol M Bator; Sugoto Chakravarty; Gregory A Skochko; Tina M Demenczuk; Adiba Watanyar; Daniel C Pevear; Michael G Rossmann
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

5.  Pocket factors are unlikely to play a major role in the life cycle of human rhinovirus.

Authors:  Umesh Katpally; Thomas J Smith
Journal:  J Virol       Date:  2007-04-11       Impact factor: 5.103

Review 6.  Viral cell recognition and entry.

Authors:  M G Rossmann
Journal:  Protein Sci       Date:  1994-10       Impact factor: 6.725

7.  Potent antiviral agent WIN 54954: high specific activity labelling with tritium.

Authors:  Judith A Egan; Richard P Nugent; Crist N Filer
Journal:  Appl Radiat Isot       Date:  2004-06       Impact factor: 1.513

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.